Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (231)	1/20/1999 8:35:00 PM
From: CPAMarty	Respond to of 2515

Do you find IMCL price action a bit poor lately? Yes, I would also like to see this stock moving up more rapidly, however, from a technical standpoint it is probably better that it builds a base here at $9 to $10. Considering its prospects, I am wondering why it hasn't tested recent highs of $14 area. I am becoming suspicious, esp. after recent presentation at H&Q. Last year was a poor one for small biotechs. All the $ is chasing high tech at the moment; when they start to take their profits the $ will, IMHO, flow back into the biotech sector which is currently undervalued. Coverage by some more analysts is key and management is working on this. To allay your suspicion, you should call IMCL IR, Andrea F. Rabney Director, Corporate Development & Investor Relations ImClone Systems Incorporated 180 Varick Street New York, NY 10014 Phone: (212) 645-1405 She is very efficient and responsive, and having spoken with her recently, i believe that she will tell you that the company is on track.